Jonathan Aschoff Recent News
Focalin Sales May Be Weak...But It Won't Hurt This Stock
Merrimack Pharma Could Have FDA Approval Coming; These Analysts Are Buying
Tetraphase's Stock Just Lost 80%, You Should Flush It...Right?
Alexion Pharmaceuticals Is Still A Buy, Despite Rx Kanuma's Review-Date Delay
Biotech Pair Trade? Brean Weighs In On Keryx Biopharma And Rockwell Medical
Cantor, Brean Capital Like Celldex Therapeutics Following Positive Data For Brain Tumor Therapy
Is Keryx Still A Good Buy After Weak Prescription Data?
Analyst: Chimerix Govt. Smallpox Pact Worth Up To $435 Million
Brean Capital Reiterates Buy Rating, Raises PT On Medivation As Xtandi Deserves To Move Upstream
Is Tetraphase Pharmaceuticals A Buyout Candidate? Brean Capital Thinks So
Brean Predicts 'A Skid And A Crash' For Rockwell Medical's Triferic Drug
UPDATE: Brean Capital Raises PT On Chimerix On Broad Antiviral Coverage
Brean Capital's Top Ideas For 2015
UPDATE: Brean Capital Reiterates On Regeneron Pharmaceuticals On Increased Confidence
Brean Capital Sees No Surprises In 3Q14 Report For Repros Therapeutics
UPDATE: Brean Capital Lowers PT on Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss
Dendreon Plunges on Restructuring News; Stock Downgraded